Show Notes
本期播客内容来自《Scrip》杂志，精选内容涵盖截至2026年10月16日当周的生物制药行业的商业动态。本期节目采用人工智能文本转语音及语音仿真技术制作。
本周内容包括：Tremfya从Stelara的余烬中崛起；辉瑞将成熟品牌作为试验田；中国科研力量在第三季度交易中大放异彩；Argenx在自身免疫领域取得进展与遭遇挫折；日本力图重振生物制药竞争力。
向听众们简要更新一下：Scrip现在已在Spotify和Apple Podcasts上开设了专属播客频道。
Feedback: [email protected]
More from Scrip Podcasts
Ahead of the awards presentation on Dec 2, the Scrip Awards podcast speaks to Mathai Mammen, CEO of Parabilis, one of the shortlisted companies for Biotech of The Year.
Join us for an audio catch-up on the major events in the global biopharma industry over the past week, as reported by Scrip’s global team, in this podcast version of Five Must-Know Things.
Join us for an audio catch-up on the major events in the global biopharma industry over the past week, as reported by Scrip’s global team, in this podcast version of Five Must-Know Things.
本期播客内容来自《Scrip》杂志，精选内容涵盖截至2026年10月9日当周的生物制药行业的商业动态。本期节目采用人工智能文本转语音及语音仿真技术制作。本周内容包括：中国带来的竞争威胁；第三季度并购活动降温；新型肺炎球菌疫苗竞争者；西班牙生物技术公司的战略；以及盐野义制药20亿美元的收购案。
Despite significant scientific progress in neuroscience, clinical trial success rates remain low. Complex diseases, evolving therapeutic approaches and challenges around endpoint selection continue to make development difficult.